Calls › LMT › Oct 23, 2026

LMT Neutral Lockheed Martin Corporation · Industrials

Real fundamentals, spent catalyst.

Published Oct 23, 2026 · Horizon 3-6 months Audited

Edgenone claimed

Evidence7/10

Entry (close)

$589.91 2026-10-22

Since publish

+5.6% to 2026-10-27

vs SPY

+4.9%

3-month verdict

Closes 2027-01-21

Thesis

The technical signal is confirming a genuine earnings-driven re-rating: Q3 2026 EPS of $7.97 vs $7.52 expected, revenue +11%, FY26 guidance raised across sales/EPS/FCF, and record backlog of $292B including the $52.5B PAC-3 MSE multiyear award. The prior 27% drawdown was driven by one-off program charges ($950M classified reach-forward loss) and F-35 lot timing, both largely resolved. However, the re-rating has already happened: the stock sits ~2-4% below consensus targets at a multiple above its historical norm, with sell-side EPS estimates drifting down over 90 days despite the guidance raise. Fundamentals support holding, not chasing.

Bull case

Record backlog (+27% q/q) gives multi-year revenue visibility; the FY27 budget supercycle (munitions tripling, PAC-3 MSE $12.2B, THAAD $11.4B, Golden Dome) plays directly to LMT's missile and space franchises; the 2025-26 charges are behind it and F-35 framework for up to 850 jets restores Aero visibility. If Q4 margins confirm, skeptical EPS estimates chase upward and the stock re-rates through $634 toward the $670-756 target range.

Bear case

This is a gap-chase at the top of a recovery move: RSI 82, catalyst spent, 2-4% to consensus value, multiple above historical norm. Fixed-price/classified program risk is structural — one bad program erased $1.6B in 2025. Aero guidance was nudged down on F-35 timing, RMS grows only low-single-digits, EPS revisions are drifting down, and the Golden Dome/munitions upside is hostage to an unpassed reconciliation bill. Bernstein ($564), TD Cowen ($570), and Goldman ($498) all sit below the current price.

What would change our mind

Q4 2026 segment operating margin prints materially below ~10.6% or new program charges appear — confirms the 'earnings quality is cyclical' bear case
FY27 EPS consensus (~$32.79) gets revised down while the stock holds >20x — the re-rating thesis is dead
Reconciliation/defense appropriation fails or Golden Dome funding is stripped — removes the FY27 growth leg
Conversely, a pullback to ~$540-560 (50-day / Bernstein target zone) with estimates intact would invalidate the 'no edge' stance and create a buyable entry

**LMT's move is a post-earnings rerating.** The chart should show the sharp gap-up recovery after earnings, supporting that fundamentals improved but the easy upside likely already re-rated into the stock.

Since publication vs SPY · closed horizons are frozen

1 weekrunning

+4.9%

+5.6% raw

1 monthrunning

+4.9%

+5.6% raw

3 monthsrunning

+4.9%

+5.6% raw

6 monthsrunning

+4.9%

+5.6% raw

The full research everything the view rests on

Direct answer to the question asked

LMT's rally is fundamentally backed — a clean Q3 beat, broad guidance raise, record $292B backlog, and resolution of the 2025-26 program charges — so this is not a classic momentum trap. But the scan is catching a post-earnings gap, not a fresh setup: at ~$607 the stock trades at ~20x FY26 EPS (above its 5-year average) with only 2-4% implied upside to consensus targets and RSI at 82. The right move is to wait for a pullback rather than chase; risk/reward at current price is roughly symmetric.

Where the edge would come from

What the price assumes

At ~20x FY26 consensus EPS of $30.41 and targets clustered at $620-634, the market has priced in continued execution: margin delivery near 10.6-10.8% segment operating margin, F-35 ramp without new charges, and at least partial conversion of the FY27 budget request (including munitions tripling and Golden Dome) into booked orders. The 45% hold contingent suggests consensus itself is unconvinced there's more near-term upside.

Why the market may be wrong

Two directions. Bullish: consensus EPS estimates fell ~0.8% over 90 days even as management raised guidance — if Q4 confirms margin delivery, estimates must chase upward, and a stock at 20x with accelerating revisions re-rates. Bearish: ~$17.1B of Golden Dome funding sits in an unpassed reconciliation bill, F-35 Aero segment guidance was quietly nudged down on award timing, and the fixed-price/classified program exposure that produced $1.6B of charges in 2025 is structural, not fixed.

The one thing to watch

The tell is the estimate-revision divergence: management raised FY26 EPS guidance by $0.25 at midpoint while the sell side cut its EPS estimates ~0.8% over 90 days — the market is underwriting revenue but not margins. The variable to watch is not backlog or budget headlines; it is whether Q4 segment operating margin prints at/above ~10.6%, because that resolves who is right and determines whether 20x is a floor or a ceiling.

Key evidence (9)

Q3 2026 (reported 2026-10-22): EPS $7.97 vs $7.52 est; revenue $20.7B (+11% y/y) vs $20.48B est [company IR, T4; corroborated Reuters]
Record backlog $292B, +27% q/q, including $52.5B PAC-3 MSE multiyear award [company IR]
FY26 guidance raised: sales midpoint +$250M to ~$81B, EPS to $30.35-30.75, FCF +$800M to $7.8-8.0B [company IR, 2026-10-22]
90-day revisions: revenue estimates +2.1%, EPS estimates -0.8% despite guidance raise [consensus aggregation, T4]
Valuation ~20x FY26 EPS vs. above 5-yr average and sector median; 'fair, not cheap' [T4 commentary]
Consensus targets $620-634 vs price ~$607 → 2-4% implied upside; mix 11 buy/10 hold/1 sell [MarketBeat/Barron's/MarketScreener, T4 — treat directionally]
Prior drawdown drivers: $950M classified reach-forward loss, $1.6B total Q2'25 charges, F-35 lot timing; FY25 EPS $21.49 vs FY23 $27.55 shows earnings cyclicality [SEC XBRL + company disclosures]
Technicals: +10.75% 1w on 2.4x volume, RSI 82.6, 12.3% below 52w high — recovery, not breakout [market data, 2026-10-22]
FY27 budget request ~$1.5T with missile procurement ~3x to ~$95B, but ~$17.1B of Golden Dome in unpassed reconciliation [CRS/DoD, T1; CSIS, T4]

Catalysts and risks

Catalysts

Q4 2026 earnings (January 2027) — margin print and first FY27 guidance
FY27 appropriations / reconciliation vote — fate of ~$350B mandatory defense funding and Golden Dome
F-35 Lot 19/20 contract award (pushed toward 2027)
Sell-side EPS revision direction over next 90 days
Further multiyear munitions awards converting budget into backlog

Risks

New fixed-price/classified program charges (structural, precedent set in 2025)
Reconciliation failure or CR delays pushing Golden Dome/new-start revenue out
F-35 award timing slipping further; Aero guide already trimmed
Mean reversion from RSI-82 overbought condition after catalyst exhaustion
Multiple compression if FY27 consensus (~$32.79) gets cut on margin skepticism

What to watch

90-day EPS revision trend — does it turn positive after the guidance raise?
Q4 segment operating margin vs. the ~10.6% implied full-year level
F-35 lot award timing announcements
Congressional action on reconciliation and FY27 defense appropriations
Whether price holds the post-earnings gap or fills back toward $540-560
NOC/RTX/GD earnings to separate LMT alpha from sector beta (peer multiples remain unverified)

Market snapshot when the call was made 2026-10-22

Price

Return 1w	+10.8%
Return 1m	+12.4%
Return 3m	+1.2%
Return 6m	+12.1%
Return 1y	+22.9%
From 52-week high	-12.2%
Realized vol, 20d	33%
SPY 3m / 1y	+3.4% / +13.8%
QQQ 3m / 1y	+3.0% / +15.2%

Technicals

LMT technicals as of 2026-10-22: last close $589.91; 20d SMA 523.24 (bearish); 50d SMA 540.01; 12d EMA 541.22; 26d EMA 533.47; RSI 14 82.6 (overbought); 20d vol 33.3%; volume x2.4 vs 20d avg

Sources (28 · T1 = primary filings)

Want a fresh look at LMT, or another name?

Queue a new deep-research run. Published to the feed when done.

Automated research opinion, published as-is on Oct 23, 2026. Not personalised advice. Figures use end-of-day closes.